共 124 条
[1]
Afifi S(2015)Role of histone deacetylase inhibitors in relapsed refractory multiple myeloma: a focus on vorinostat and panobinostat Pharmacotherapy 35 1173-1188
[2]
Michael A(2012)Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy DNA Cell Biol 31 S62-S71
[3]
Azimi M(2010)Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia Eur J Cancer 46 1781-1789
[4]
Rodriguez M(2010)Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease Proc Natl Acad Sci USA 107 12617-12622
[5]
Lendvai N(2010)Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation Leukemia 24 1412-1421
[6]
Landgren O(2013)SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation Oncogene 32 4913-4920
[7]
Ahmad M(2013)Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer J Cancer Res Clin Oncol 139 1507-1514
[8]
Boschelli F(2011)Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma Br J Cancer 104 957-967
[9]
Arndt K(1999)Total synthesis and biological activity of lactacystin, omuralide and analogs Chem Pharm Bull 47 1-10
[10]
Gambacorti-Passerini C(2011)A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients J Hepatol 54 629-639